Agoracom Blog

AI/ML Innovations $AIML.ca $FIRZF Retains North Equities Corp $ADK.ca $DM.ca $PFM.ca

Posted by AGORACOM-AB at 12:42 PM on Thursday, February 25th, 2021
AI/ML Innovations Inc.

TORONTO, ON / ACCESSWIRE / February 25, 2021 / AI/ML Innovations Inc. (CSE:AIML), a company focused on acquiring and advancing Artificial Intelligence/Machine Learning technologies that address urgent societal needs, reports that it has engaged Toronto-based marketing firm North Equities Corp. (“North Equities”) that specializes in various social media platforms, to facilitate greater investor engagement and widespread dissemination of the Company’s news.

In addition to press releases, the Company will be posting important information and updates through videos on the official Company YouTube Channel: https://www.youtube.com/channel/UCCfOj2P_Fu3TOK6Jl1G9vEQ

In accordance with the terms of the agreement, the Company will issue 80,645 common shares at a deemed price of $1.24 per share to North Equities, for a 6-month engagement ending 15/08/21. These shares are subject to a statutory hold period ending 24/06/21.

Read More: https://agoracom.com/ir/AIMLInnovations/forums/discussion/topics/756055-ai-ml-innovations-retains-north-equities-corp/messages/2305330#message

Molecule $MLCL.ca Engages North Equities Corp. for Digital Marketing and PR Services $TPX.A.ca $ACB.ca $WEED.ca

Posted by AGORACOM-AB at 11:43 AM on Thursday, February 25th, 2021
Molecule

February 25, 2021 – TheNewswire – Ottawa,  Ontario – Molecule Holdings Inc. (C NSX :MLCL. CN )  (“ Molecule ” or the “ Company ”), a Canadian craft-focused cannabis beverage production company, is pleased to announce that it has engaged Toronto-based marketing firm North Equities Corp. (“ North Equities ” or “ NE ”), which specializes in various social media platforms, to facilitate greater investor engagement and widespread dissemination of the Company’s news.

In addition to press releases, the Company will be posting important information and updates through videos from the official Company YouTube Channel .

Pursuant to the terms of the agreement between the Company and North Equities (the “Agreement”), the Company has issued North Equities 500,000 common shares at a price of $0.14 per share as payment of $70,000 invoiced to the Company. No further payments are due for the duration of the Agreement’s 6 month term. The common shares issued to North Equities are subject to a hold period expiring on June 24, 2021.

Read More: https://agoracom.com/ir/MoleculeHoldings/forums/discussion/topics/756061-molecule-engages-north-equities-corp-for-digital-marketing-and-pr-services/messages/2305338#message

Victory Square Technologies $VST.ca $VSQTF Announces GameOn Share Dividend Initiative for VST Shareholders $NTAR.ca $SEV.ca $DBO.ca $YDX.ca

Posted by AGORACOM-AB at 11:40 AM on Thursday, February 25th, 2021

As part of the Company’s long-term strategy to maximize shareholder value, the Victory Square Technologies board of directors has approved a strategic initiative to unlock the intrinsic value of its portfolio company, GameOn Entertainment Technologies Inc. by proposing a dividend distribution of a portion of the common shares of GameOn held by the Company at the time of listing of the Shares to the shareholders of the Company.

VANCOUVER, British Columbia, Feb. 25, 2021 (GLOBE NEWSWIRE) — Victory Square Technologies Inc. (“Victory Square” or the “Company”) (CSE:VST) (OTC:VSQTF)(FWB:6F6) is pleased to announce that, as part of the Company’s long-term strategy to maximize shareholder value, the board of directors of the Company has approved a strategic dividend reward initiative to unlock the intrinsic value of its portfolio company, GameOn Entertainment Technologies Inc. (“ GameOn ”) by proposing a distribution of a portion of the common shares of GameOn currently held by the Company to shareholders of the Company. Victory Square will evaluate, consider and assess the mechanism by which to effect such distribution on a tax efficient and financially prudent basis, with the aim of ultimately capitalizing GameOn as a stand-alone publicly listed entity, following its public listing.

Shafin Diamond Tejani, Chief Executive Officer of Victory Square, commented: “The objective of the share dividend initiative is to reward the Company’s shareholders with equity in GameOn as it progresses towards listing as a standalone publicly traded company. This will also enable the capital markets to appropriately value one of our portfolio investments.”

“This is the first of what we hope to be many share dividend initiatives that we wish to provide VST shareholders as we grow and realize appreciating assets,” said Tejani.

Founded in 2018, GameOn Entertainment Technologies empowers sports and entertainment content providers with the world’s simplest and most accessible gamification platform.

Read More: https://agoracom.com/ir/VictorySquareTechnologies/forums/discussion/topics/756057-victory-square-technologies-announces-gameon-share-dividend-initiative-for-vst-shareholders/messages/2305334#message

ORTHO REGENERATIVE TECHNOLOGIES $ORTH.ca $ORTIF ADDS PATRICK O’DONNELL TO BOARD OF DIRECTORS

Posted by AGORACOM-AB at 11:40 AM on Thursday, February 25th, 2021
Ortho

Montreal, QC, February 24, 2021 – Ortho Regenerative Technologies Inc. (CSE: ORTH, OTCQB: ORTIF) (“Ortho RTI” or the “Company”), a clinical stage orthobiologics company focused on the development of novel soft tissue repair regenerative technologies, announced today the appointment of Patrick O’Donnell to its Board of Directors, effective immediately. 

“We are very pleased to welcome Patrick to the Ortho RTI Board of Directors to help lead a very important transition in the development of our company, as we prepare to start our first U.S. multisite Ortho-R rotator cuff tear repair Phase I/II clinical trial”, said Claude LeDuc, President and Chief Executive Officer of Ortho RTI. “Ortho RTI will greatly benefit from Patrick’s company-building experience as well as his expertise in the development and management of strategic partnerships fund-raising, commercial, clinical, regulatory and reimbursement strategies, all specific to our industry. We are looking forward to his insightful contribution to our Board”. 

Commenting on his appointment to Ortho RTI’s Board of Directors, Mr. O’Donnell said: “I am happy to be joining the Board of Directors of Ortho RTI. The Company’s proprietary technology platform has the potential to help address significant unmet medical needs in a multitude of soft tissue repair related indications. I am excited to help Ortho RTI develop into an orthobiologics industry leader”. 

Read More: https://agoracom.com/ir/OrthoRegenerativeTechnologies/forums/discussion/topics/755959-ortho-regenerative-technologies-adds-patrick-o-donnell-to-board-of-directors/messages/2305098#message

TAAT Lifestyle & Wellness Ltd. $TAAT.ca $TOBAF Brings ‘Same Format, Different Ingredients’ Model to Smoking Market $BYND $INGR $MO $TPB

Posted by AGORACOM-AB at 9:54 AM on Thursday, February 25th, 2021
TAAT

NEW YORK, Feb. 25, 2021 (GLOBE NEWSWIRE) — NetworkNewsAudio – TAAT(TM) Lifestyle & Wellness Ltd. (CSE: TAAT) (OTCQB: TOBAF) announces the availability of a broadcast titled, “Beyond Tobacco: TAAT Innovation Delivers New Smoking Alternative.”

To hear the AudioPressRelease, please visit: The NetworkNewsAudio News Podcast

To view the full editorial, please visit: https://www.nnw.fm/e5KjQ

Health and wellness has become a top priority in today’s world, creating a global climate of consumers clamoring for choices that offer the same experiences they’ve come to enjoy but with different ingredients.

This is on full display with the surging popularity of alternative food and beverages that create the same feeling that one is accustomed with only a change in ingredients. Today, burgers and seafood look, smell and taste like hamburger and crabmeat, respectively, while being made from plants.

Read More: https://agoracom.com/ir/TAAT/forums/discussion/topics/756068-taat-lifestyle-wellness-ltd-cse-taat-otcqb-tobaf-brings-same-format-different-ingredients-model-to-smoking-market/messages/2305349#message

Draganfly $DFLY.ca $DFLYF CEO Cameron Chell Will Speak at Canaccord Genuity Inaugural Global Sustainability Event $FLT.ca $UAVS $ALPP

Posted by AGORACOM-JC at 9:37 AM on Thursday, February 25th, 2021
  • Cameron Chell, will speak on the Sustainability/Rethinking Impact 2021 panel hosted by Canaccord Genuity.
  • The virtual event takes place on March 4, 2021 at 10AM PST/1PM EST.

Los Angeles, CA, Feb. 25, 2021 — Draganfly Inc. (CSE: DFLY) (OTCQB: DFLYF) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading manufacturer and systems developer‎, announced today that the CEO of the Company, Cameron Chell, will speak on the Sustainability/Rethinking Impact 2021 panel hosted by Canaccord Genuity.

The virtual event takes place on March 4, 2021 at 10AM PST/1PM EST. Cameron Chell will join a panel to discuss: Rethinking Autonomy and the Drone Economy moderated by Ken Herbert, Managing Director, Canaccord Genuity Equity Research. The panel will focus on drones and their disruptive potential in the package delivery and logistics markets,

“I am honored to be part of Canaccord’s inaugural Global Sustainability Event,” said Cameron Chell, CEO of Draganfly. “Canaccord has put together aligned research across multiple geographies and I look forward to discussing how Draganfly has been a disruptive force in the health tech and drone delivery markets.”

To learn more about the event visit: https://www.canaccordgenuity.com/capital-markets/about-us/events/ .

Read More: https://agoracom.com/ir/Draganfly/forums/discussion/topics/756067-draganfly-ceo-cameron-chell-will-speak-at-canaccord-genuity-inaugural-global-sustainability-event/messages/2305347#message

Mountain Valley MD $MVMD $MVMDF Confirms Quicksome™ License Agreement, First Revenues $CTLT $MRNA $NVAX

Posted by AGORACOM-Eric at 9:18 AM on Thursday, February 25th, 2021
This image has an empty alt attribute; its file name is MVMD-Small.png
  • Entered a commercial license agreement with that is focused on the rapidly emerging global mushroom space.
  • Based on applying MVMD’s Quicksome™ technology to mushroom nutraceutical products
  • Initial payment in the amount of $250,000 CAD

Mountain Valley MD Holdings Inc. (the “Company” or “MVMD“) (CSE: MVMD) (FRA: 20MP) (OTCQB: MVMDF) is pleased to announce that Mountain Valley MD Inc. (“Mountain Valley“) has finalized and entered into a commercial license agreement with Circadian Wellness Corp. (“Circadian“), a privately held Ontario corporation that is focused on the rapidly emerging global mushroom space.

The license agreement with Circadian is based on applying MVMD’s Quicksome™ technology to mushroom nutraceutical products in consideration of ongoing product royalties and an initial payment in the amount of $250,000 CAD, made up of $200,000 CAD cash and $50,000 CAD of equity shares in Circadian.  The initial payment monies will be applied to formulation, product development and sample development work and represents the Company’s first revenues.

MVMD has been working closely with Circadian on proprietary formulations for mushroom-infused products that achieved a significant increase in overall molecule efficacy with the Company’s Quicksome™ desiccated liposome technology applied across a variety of rapid dissolve oral products.  Circadian is finalizing its product plans and go-to-market strategy for a broad line of naturally derived mushroom products that will be distributed initially in North America and expanded globally in future phases.

“Embedding Mountain Valley MD’s Quicksome™ technology into our unique mushroom product formulations has allowed us to create a product line that we believe will be unmatched in its efficacy in the marketplace,” stated Dr. Sanjeev Goel, Chief Medical Officer at Circadian Wellness and founder of Peak Human Labs. “The initial consumer testing with our energy and sleep products has been very well received.  The precision of this delivery technology allows us to build the functional mushroom business out while simultaneously pursuing a leadership position in the rapidly emerging psychedelic space.”

Circadian is a privately held Ontario corporation in the business of mushroom cultivation, extraction, clinical research and development, and end-user consumer health and wellness products and retreats (www.circadianwellness.com).

“With our focus on providing our global nutraceutical, vaccine and pharmaceutical partners with unprecedented product and market advantages, we believe our partnership with Circadian Wellness is a perfect bullseye for our value proposition across the health and wellness space,” stated Dennis Hancock, President and CEO of Mountain Valley MD.  “This inroad into the rapidly growing mushroom industry timed with the broadening analyst coverage of the numerous scientific benefits of mushrooms on human health are expected to be significant for our business plan at Mountain Valley MD.”

“Our ability to drive an increase in bioavailability across convenient and easy-to-use rapid dissolve oral delivery formats provides numerous product advantages that we believe will position Circadian Wellness products as the preeminent choice for consumers in the rapidly growing mushroom marketplace,” stated Mike Farber, Director of Life Sciences at Mountain Valley MD.

Read More: https://agoracom.com/ir/MountainValleyMD/forums/discussion/topics/756066-mountain-valley-md-confirms-quicksome-license-agreement-first-revenues/messages/2305344#message

MedX $MDX.ca Announces Final Closing of $4 Million Convertible Debenture Loan Notes Non-brokered Private Placement $DMTK $LMD.ca $DOC.ca $DOCRF $WELL.ca $PRN.ca

Posted by AGORACOM-JC at 9:11 AM on Thursday, February 25th, 2021
Home - MedX Health
  • Closed on the final $1.4 million of the $4 million Non-brokered Private Placement of 80 Convertible Debenture Loan Notes
  • Each with a face value of $50,000, as originally announced in its Press Release dated January 25, 2021. Previous Closings were announced earlier in February 2021

MedX Health Corp. (“ MedX ” or the “ Company ”) (TSX-V: MDX) is pleased to announce that it has closed on the final $1.4 million of the $4 million Non-brokered Private Placement of 80 Convertible Debenture Loan Notes, each with a face value of $50,000 (“Convertible Notes”), as originally announced in its Press Release dated January 25, 2021. Previous Closings were announced earlier in February 2021.

Full Details of each of the Closings are as follows:

  • First Closing on January 27, 2021: $2 million, with cash commissions of $114,000 and issuance of 300,000 Broker Warrants;
  • Second Closing on January 28, 2021: $500,000, with cash commissions of $15,000 and issuance of 107,143 Brokers Warrants;
  • Third Closing on February 3, 2021: $100,000, with no cash commissions and no Brokers Warrants;
  • Fourth, and final Closing, on February 23, 2021: $1.4 million, with cash commissions of $81,000 and issuance of 578,576 Brokers Warrants.

The Convertible Notes will bear interest at 6% per year, payable Quarterly, and will mature on December 31, 2023 (the “Maturity Date”). The Convertible Notes may be converted, at the option of the Holder, into units at $0.14 per unit (“Unit”) at any time until the Maturity Date. Each Unit will be comprised of One (1) fully paid Common Share and One-half (1/2) of a Share Purchase Warrant. Each whole Share Purchase Warrant will be exercisable to purchase One (1) further Common Share at the price of $0.20, exercisable for a period expiring on the Maturity Date. The Convertible Notes, and any underlying securities, are subject to restriction from trading for a period of 4 months and one day from the respective dates of issuance. Qualified Agents received commissions in respect of subscriptions introduced by them by way of cash equal to 6% of funds so introduced, and issuance of agent’s warrants (“Agent’s Warrant(s)”) calculated by reference to 6% of the funds from subscribers introduced by such Agent. Each Agent’s Warrant, which is non-transferable, will be exercisable to acquire one Unit at $0.14 per Unit, at any time during the period up to the Maturity Date. A total of $210,000 of cash commissions were paid, and 985,719 Agent’s Warrants have been issued. The Agent’s Warrants, and any underlying securities, are restricted from trading for a period of four months and one day from their respective dates of issuance.

MedX’s CEO, Rob von der Porten stated, “We believe this financing clearly demonstrates a vote of confidence in our strategic direction and ability to be a leader in the teledermatology space. This funding is significant to furthering the development of our sales initiatives and advancing MedX’s Dermsecure TM platform to a wider global network.”

About MedX

MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin health with its SIAscopy on DermSecure™ telemedicine platform, utilizing its SIAscopy™ technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA, TGA and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union, Turkey and Brazil. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.

Read More: https://agoracom.com/ir/MDX/forums/discussion/topics/756059-medx-announces-final-closing-of-4-million-convertible-debenture-loan-notes-non-brokered-private-placement/messages/2305336#message

Red Light Holland $TRIP.ca $TRUFF iMicrodose Pack Receives Authorization for the First Legal Import and Sale of Psilocybin Truffles to Brazil $RVV.ca $PSYC $FTRP $BUZZ

Posted by AGORACOM-Eric at 8:53 AM on Thursday, February 25th, 2021
https://i.ibb.co/ZdKv64V/Red-Light-Holland-Square.jpg
  • iMicrodose packs, which contain 15g of Psilocybin Truffles, to be legally imported to Brazil
  • To be imported and sold in Brazil for Medical use
  • Approval and shipment represent a significant advancement in opening the legal and medically approved market for psilocybin in Brazil

Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC: TRUFF) (“Red Light Holland” or the “Company“), an Ontario-based corporation engaged in the production, growth and sale of a premium brand of magic truffles to the legal, recreational market within the Netherlands, is extremely pleased to announce that Anvisa, Brazil’s National Health Regulatory Agency, has granted authorization for the Company’s iMicrodose packs, which contain 15g of Psilocybin Truffles, to be legally imported to Brazil via the ‘named patient import process’ for prescribed medical patient use.

“We are grateful for our collaborative relationship with Disruptive Pharma who worked closely with the Brazilian Health Regulatory Agency to secure authorization to import Red Light Holland’s iMicrodose packs, with our natural-occurring branded Psilocybin Truffles, to be imported and sold in Brazil for Medical use, as our branded iMicrodose packs have officially been prescribed by a doctor to a patient in Brazil,” said Todd Shapiro, CEO and Director of Red Light Holland. “This is a monumental day for the Company, and we are so proud to be a part of providing legal access of psilocybin to Brazil and for the first time having our product prescribed by a physician for medical use.”

Red Light Holland’s iMicrodose packs have been shipped to Disruptive Pharma’s MyPharma2Go logistics hub in the Netherlands to start their journey to Brazil. Once landed in Brazil, MyPharma2Go is expected to deliver the iMicrodose packs to a Brazilian patient as they have been pre-prescribed by a physician, before the end of March 2021.

This approval and shipment represent a significant advancement in opening the legal and medically approved market for psilocybin in Brazil, a country with a population of over 200 million people. Shapiro added: “This early process working alongside Disruptive Pharma’s MyPharma2Go.com, a large Brazilian online pharmaceutical and supplement distributor, has been an absolute pleasure and one we are thankful for. We are pleased to do our part to potentially be a part of positive change in Brazil, and to steal a line from Neil Armstrong: This is one micro step for man, one macro leap for mankind.”

Red Light Holland and Disruptive Pharma continue to work towards finalizing their proposed joint venture structure and agreement, as previously disclosed in the Company’s news release dated December 14, 2020. In consideration for Disruptive Pharma having met these initial milestones, the Company has agreed to issue to Disruptive Pharma, 3,000,000 common share purchase warrants, each warrant is exercisable into one common share of the Company at a price of $0.50 per share for a period of 2 years. 750,000 of these warrants have vested immediately based on Disruptive Pharma having fulfilled these milestones, the balance vest upon future milestones being met. These warrants and any underlying shares issued upon exercise, are subject to a statutory hold period of 4 months and 1 day.

Read More: https://agoracom.com/ir/RedLightHolland/forums/discussion/topics/756065-red-light-holland-imicrodose-pack-receives-authorization-for-the-first-legal-import-and-sale-of-psilocybin-truffles-to-brazil/messages/2305343#message

Xali Gold $XGC.ca Delineates Drilling Targets at El Dorado $FMG.ca $MEX.ca $AGI.ca $DSV.ca

Posted by AGORACOM-Eric at 8:35 AM on Thursday, February 25th, 2021

Xali Gold Corp. (TSXV:XGC) (“Xali Gold” and/or the “Company”) is pleased to advise that new drill targets have been delineated on the El Dorado Gold-Silver Project, located in Nayarit State, Mexico through the development of a new 3D geological model. The new model indicates high grade mineralization occurring in multiple parallel veins such that future mining could focus on several veins at once to potentially allow reduced mining costs. Drilling is planned to test potential lateral extensions to the high grade zone.

Permitting applications are in progress for the drilling which are expected to take 3 to 4 months to receive. Permit applications are also being prepared for the reopening of the historical Hundida Mine and should take 6 to 10 months to receive. Mineralization is planned to be shipped from this area to the nearby SDA plant under acquisition from Magellan Acquisitions.

The El Dorado vein system has a history of small-scale mining from two veins in the Hundido and El Dorado mines (see News Release April 28, 2020) but four veins with parallel high-grade zones have been delineated in the new model. Additionally, several vein targets have been identified along trend for follow-up exploration.

Prospero Silver Corp. (“Prospero”) explored the El Dorado property between 2010 and 2011. Their drilling intersected multiple steeply-dipping silicified mineralized zones extending from near-surface to the 180 metre (“m”) drilled depth and over a strike length of 440m.   Prospero intersected grades ranging from 3 to 40 grams per tonne (“gpt”) gold and 57 to 500 gpt silver over true widths ranging from 0.52 to 11.2 m. (http://www.candentegold.com/i/maps/sedardoc4391012.pdf)

Significant results reported by Prospero on Dec 10, 2010 included:

  • 16.17m grading 4.03 g/t gold, 204 g/t silver, 4.0% lead, and 1.75% zinc; and 2.32m grading 6.04 g/t gold and 140 g/t silver in hole DOR-10-11. (http://www.candentegold.com/i/maps/Prospero-NR–December-10,-2010.pdf)

Read More: https://agoracom.com/ir/XaliGold/forums/discussion/topics/756062-xali-gold-delineates-drilling-targets-at-el-dorado/messages/2305340#message